Metastatic Breast Cancer Therapeutics
1. Faslodex patent expiration
Treatment: Treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen ther...
FASLODEX IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6774122 (Pediatric) | ASTRAZENECA | Formulation |
Jul, 2021
(4 years ago) | |
|
US8466139 (Pediatric) | ASTRAZENECA | Formulation |
Jul, 2021
(4 years ago) | |
|
US8329680 (Pediatric) | ASTRAZENECA | Formulation |
Jul, 2021
(4 years ago) | |
| US7456160 | ASTRAZENECA | Formulation |
Jan, 2021
(5 years ago) | |
| US8466139 | ASTRAZENECA | Formulation |
Jan, 2021
(5 years ago) | |
| US8329680 | ASTRAZENECA | Formulation |
Jan, 2021
(5 years ago) | |
| US6774122 | ASTRAZENECA | Formulation |
Jan, 2021
(5 years ago) | |
|
US7456160 (Pediatric) | ASTRAZENECA | Formulation |
Jul, 2021
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-126) | Sep 09, 2013 |
| Pediatric Exclusivity(PED) | Mar 09, 2014 |
| M(M-103) | May 17, 2014 |
| M(M-123) | Nov 09, 2015 |
| New Indication(I-725) | Feb 19, 2019 |
| New Indication(I-749) | Aug 25, 2020 |
Drugs and Companies using FULVESTRANT ingredient
Market Authorisation Date: 25 April, 2002
Dosage: SOLUTION
How can I launch a generic of FASLODEX before it's drug patent expiration?
More Information on Dosage
FASLODEX family patents
2. Halaven patent expiration
Treatment: Treatment of patients with metastatic breast cancer
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8097648 | EISAI INC | Methods and compositions for use in treating cancer |
Jan, 2021
(4 years ago) | |
| US6469182 | EISAI INC | Intermediates in the preparation of macrocyclic analogs |
Jun, 2019
(6 years ago) | |
| US7470720 | EISAI INC | Methods and compositions for use in treating cancer |
Jun, 2019
(6 years ago) | |
| US6214865 | EISAI INC | Macrocyclic analogs and methods of their use and preparation |
Jun, 2019
(6 years ago) | |
|
US6214865 (Pediatric) | EISAI INC | Macrocyclic analogs and methods of their use and preparation |
Jan, 2024
(1 year, 11 months ago) | |
| USRE46965 | EISAI INC | Intermediates for the preparation of analogs of Halichondrin B |
Jan, 2027
(11 months from now) | |
|
USRE46965 (Pediatric) | EISAI INC | Intermediates for the preparation of analogs of Halichondrin B |
Jul, 2027
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2015 |
| New Indication(I-721) | Jan 28, 2019 |
| Orphan Drug Exclusivity(ODE) | Jan 28, 2023 |
| Orphan Drug Exclusivity(ODE-107) | Jan 28, 2023 |
| M(M-280) | Sep 13, 2025 |
| Pediatric Exclusivity(PED) | Mar 13, 2026 |
Drugs and Companies using ERIBULIN MESYLATE ingredient
NCE-1 date: 13 March, 2025
Market Authorisation Date: 15 November, 2010
Dosage: SOLUTION
How can I launch a generic of HALAVEN before it's drug patent expiration?
More Information on Dosage
HALAVEN family patents
3. Ibrance patent
expiration
Treatment: Palbociclib for hr-pos. her2-neg. advanced or metastatic breast cancer in combo with an aromatase inhibitor in pts as initial endocrine-base...
IBRANCE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7208489 | PFIZER | 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones |
Jan, 2023
(2 years ago) | |
| US6936612 | PFIZER | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
Jan, 2023
(2 years ago) | |
| US10723730 | PFIZER | Solid forms of a selective CDK4/6 inhibitor |
Feb, 2034
(8 years from now) | |
| USRE47739 | PFIZER | 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones |
Mar, 2027
(1 year, 1 month from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7456168 | PFIZER | 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones |
Jan, 2023
(2 years ago) | |
|
USRE47739 (Pediatric) | PFIZER | NA |
Sep, 2027
(1 year, 7 months from now) | |
|
US10723730 (Pediatric) | PFIZER | NA |
Aug, 2034
(8 years from now) | |
|
US11065250 (Pediatric) | PFIZER | NA |
Feb, 2037
(11 years from now) | |
| US11065250 | PFIZER | Solid dosage forms of palbociclib |
Aug, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-725) | Feb 19, 2019 |
| New Chemical Entity Exclusivity(NCE) | Feb 03, 2020 |
| M(M-14) | Sep 16, 2028 |
| Pediatric Exclusivity(PED) | Mar 16, 2029 |
Drugs and Companies using PALBOCICLIB ingredient
NCE-1 date: 16 March, 2028
Market Authorisation Date: 03 February, 2015
Dosage: CAPSULE
How can I launch a generic of IBRANCE before it's drug patent expiration?
More Information on Dosage
IBRANCE family patents
4. Kisqali patent expiration
Treatment: In combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negat...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9193732 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(5 years from now) | |
| US8415355 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Mar, 2031
(5 years from now) | |
| US8685980 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
May, 2030
(4 years from now) | |
| US8324225 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Jun, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9868739 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(5 years from now) | |
| US9416136 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Aug, 2029
(3 years from now) | |
| US8962630 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Dec, 2029
(3 years from now) | |
| US12064434 | NOVARTIS | Ribociclib tablet |
Apr, 2036
(10 years from now) | |
| US12419894 | NOVARTIS | NA |
Apr, 2036
(10 years from now) | |
| US10799506 | NOVARTIS | Ribociclib tablet |
Apr, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-783) | Jul 18, 2021 |
| New Indication(I-784) | Jul 18, 2021 |
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2022 |
| New Patient Population(NPP) | Dec 10, 2024 |
| New Indication(I-950) | Sep 17, 2027 |
Drugs and Companies using RIBOCICLIB SUCCINATE ingredient
NCE-1 date: 13 March, 2021
Market Authorisation Date: 13 March, 2017
Dosage: TABLET
How can I launch a generic of KISQALI before it's drug patent expiration?
More Information on Dosage
KISQALI family patents
5. Orserdu patent expiration
Treatment: Treatment of an er-positive breast cancer; Treatment of an er-positive breast cancer following at least one line of endocrine therapy
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7612114 | STEMLINE THERAP | Selective estrogen receptor modulator |
Aug, 2026
(7 months from now) | |
| US8399520 | STEMLINE THERAP | Selective estrogen receptor modulator |
Dec, 2025
(14 days ago) | |
| US10385008 | STEMLINE THERAP | Polymorphic forms of RAD1901-2HCL |
Jan, 2038
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11819480 | STEMLINE THERAP | Methods for treating cancer |
Feb, 2037
(11 years from now) | |
| US10420734 | STEMLINE THERAP | Method of treating cancer using selective estrogen receptor modulators |
Oct, 2036
(10 years from now) | |
| US10745343 | STEMLINE THERAP | Polymorphic forms of RAD1901-2HCl |
Jan, 2038
(11 years from now) | |
| US10071066 | STEMLINE THERAP | Method of treating cancer using selective estrogen receptor modulators |
Oct, 2034
(8 years from now) | |
| US11779552 | STEMLINE THERAP | Method of treating cancer using selective estrogen receptor modulators |
Oct, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2028 |
Drugs and Companies using ELACESTRANT HYDROCHLORIDE ingredient
NCE-1 date: 27 January, 2027
Market Authorisation Date: 27 January, 2023
Dosage: TABLET
More Information on Dosage
ORSERDU family patents
6. Tryptyr patent expiration
Treatment: Treatment of the signs and symptoms of dry eye disease (ded)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11850221 | ALCON LABS INC | Ophthalmic pharmaceutical compositions and uses thereof |
Dec, 2042
(16 years from now) | |
| US10028920 | ALCON LABS INC | Methods for treating occular irritation involving tearing by administering modulators of TRPM8 |
Sep, 2031
(5 years from now) | |
| US9433679 | ALCON LABS INC | Use of TRMP8 for treating opthalmic diseases or conditions involving tearing |
Sep, 2031
(5 years from now) | |
| US9095609 | ALCON LABS INC | Ophthalmic composition comprising ws-12 and methods to treat xerophthalmia |
Sep, 2031
(5 years from now) | |
| US12336971 | ALCON LABS INC | NA |
Dec, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2030 |
Drugs and Companies using ACOLTREMON ingredient
NCE-1 date: 28 May, 2029
Market Authorisation Date: 28 May, 2025
Dosage: SOLUTION/DROPS
More Information on Dosage
TRYPTYR family patents
7. Tukysa patent expiration
Treatment: Combination treatment with tucatinib and trastuzumab of adults with ras wild-type her2-positive unresectable or metastatic colorectal cancer that has progressed following previous treatment as claimed...
TUKYSA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7452895 | SEAGEN | Quinazoline analogs as receptor tyrosine kinase inhibitors |
Nov, 2025
(a month ago) | |
| US8648087 | SEAGEN | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
Apr, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11666572 | SEAGEN | Treatment of HER2 positive cancers |
Apr, 2038
(12 years from now) | |
| US11504370 | SEAGEN | Treatment of brain cancer |
Mar, 2033
(7 years from now) | |
| US12048698 | SEAGEN | Treatment of HER2 positive cancers |
Apr, 2038
(12 years from now) | |
| US9457093 | SEAGEN | Solid dispersions of a ERB2 (HER2) inhibitor |
Oct, 2032
(6 years from now) | |
| US9693989 | SEAGEN | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
May, 2027
(1 year, 3 months from now) | |
| US11207324 | SEAGEN | Treatment of HER2 positive cancers |
Apr, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2025 |
| New Indication(I-906) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-309) | Apr 17, 2027 |
| Orphan Drug Exclusivity(ODE-422) | Jan 19, 2030 |
Drugs and Companies using TUCATINIB ingredient
NCE-1 date: 17 April, 2024
Market Authorisation Date: 17 April, 2020
Dosage: TABLET
More Information on Dosage
TUKYSA family patents
8. Tykerb patent expiration
Treatment: Treatment of patients with advanced or metastatic breast cancer whose tumors overexpress her2 and who have received prior therapy including ...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8513262 | NOVARTIS | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
Jan, 2019
(7 years ago) | |
| US8821927 | NOVARTIS | Pharmaceutical composition |
Sep, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6727256 | NOVARTIS | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
Jan, 2019
(7 years ago) | |
| US6713485 | NOVARTIS | Heterocyclic compounds |
Sep, 2020
(5 years ago) | |
| US6391874 | NOVARTIS | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
Jul, 2017
(8 years ago) | |
| US7157466 | NOVARTIS | Quinazoline ditosylate salt compounds |
Nov, 2021
(4 years ago) | |
| US6828320 | NOVARTIS | Heterocyclic compounds |
Jul, 2017
(8 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2012 |
| New Indication(I-620) | Jan 29, 2013 |
| M(M-235) | Dec 06, 2021 |
Drugs and Companies using LAPATINIB DITOSYLATE ingredient
NCE-1 date: 14 March, 2011
Market Authorisation Date: 13 March, 2007
Dosage: TABLET
How can I launch a generic of TYKERB before it's drug patent expiration?
More Information on Dosage
TYKERB family patents
9. Verzenio patent expiration
Treatment: In combination with fulvestrant for the treatment of adult patients with hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or Read More
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7855211 | ELI LILLY AND CO | Protein kinase inhibitors |
Sep, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-768) | Feb 26, 2021 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2022 |
| New Indication(I-877) | Oct 12, 2024 |
| New Patient Population(NPP) | Oct 12, 2024 |
Drugs and Companies using ABEMACICLIB ingredient
NCE-1 date: 28 September, 2021
Market Authorisation Date: 28 September, 2017
Dosage: TABLET
More Information on Dosage
VERZENIO family patents